Orexo Interim Report Q4 2023, incl. Full Year Report
Positive EBITDA in H2 setting the target for FY 2024 Q4 2023 highlights› Total net revenues of SEK 166.0 m (156.1)› EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-repeating clinical trials, SEK 23.4 m (-0.1) › Net earnings of SEK -18.6 m (-91.8)› US Pharma segment (Zubsolv® US) net revenues of SEK 151.3 m (142.6), in local currency USD 14.2 m (13.3), US Pharma EBIT of SEK 75.4 m (77.0)› Cash flow from operating activities of SEK -2.6 m (-48.9), cash and invested funds of SEK 171.0 m (351.9)› Earnings per